A venture capital firm based in Europe focuses solely on the life sciences. The firm recently closed their third fund and is actively looking for new investments, usually in series A & B rounds. Typically, the firm allocates €8M-€10M over the life of the investment with about half of that amount up front, in the initial investment. The firm primarily invests in companies that are based in Europe, but will also consider opportunities in North America.
The firm invests primarily in biotech therapeutics and medical devices. For biotech, the firm invests in pre-clinical up unto phase II assets. For medical devices, the firm prefers companies with with initial clinical proof-of-concept up unto reaching regulatory approval, whether that be PMA or 510(k) approval. The firm is somewhat less interested in diagnostic technologies. The firm is agnostic in terms of subsectors and indications, including orphan indications, but is very interested in products that address clear unmet opportunities. Historically, the firm invested in biotech therapeutics that address inflammatory, orphan, respiratory, autoimmune, infectious and cardiovascular disorders. Medical device investments have included a non-active implantable device for pulmonary embolism, as well as devices for renal and cardiovascular and peripheral vascular diseases.
The firm requests a board seat in each portfolio company. The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org